经直肠超声造影联合血清微RNA-130b-3p、磷酸葡萄糖变位酶样蛋白5对早期前列腺癌的诊断价值  

Diagnostic value of transrectal contrast-enhanced ultrasound combined with serum miR-130b-3p and PGM5 in early prostate cancer

作　　者：姚灯礼 杨华 罗芳 黄睿 赵培屹 YAO Dengli;YANG Hua;LUO Fang;HUANG Rui;ZHAO Peiyi(Department of Ultrasound,the People's Hospital of Tongren,Tongren,Guizhou 554310,China)

机构地区：[1]铜仁市人民医院超声科,贵州铜仁554310

出　　处：《安徽医药》2025年第5期972-976,共5页Anhui Medical and Pharmaceutical Journal

摘　　要：目的观察早期前列腺癌病人血清微RNA-130b-3p(miR-130b-3p)、磷酸葡萄糖变位酶样蛋白5(PGM5)和经直肠超声造影参数的变化,探讨三者联合对早期前列腺癌的鉴别诊断价值。方法选取2022年5月至2023年7月铜仁市人民医院138例早期前列腺癌病人为前列腺癌组,145例前列腺良性增生病人为良性增生组,均进行经直肠超声造影检查,并采用实时荧光定量逆转录聚合酶链式反应(qRT-PCR)检测血清miR-130b-3p水平,酶联免疫吸附试验(ELISA)检测PGM5水平。各指标绘制受试者操作特征曲线(ROC曲线)分析早期前列腺癌诊断价值,曲线下面积(AUC)行Z检验;与病理结果的一致性采用Kappa一致性检验。结果前列腺癌组血清miR-130b-3p水平1.32±0.35及超声造影参数中梯度(1.76±0.43)dB/s、峰值强度(15.27±0.64)dB显著高于良性增生组[1.02±0.24、(1.35±0.34)dB/s、(14.35±0.27)dB],血清PGM5(3.35±0.71)μg/L显著低于良性增生组(4.24±1.06)μg/L(P<0.05)。经直肠超声造影、miR-130b-3p、PGM5单独及联合鉴别诊断早期前列腺癌的AUC分别为0.86、0.80、0.81、0.93,联合AUC高于单独AUC(P<0.05)。经直肠超声造影单独及联合血清指标检查结果与病理结果的Kappa一致性系数分别为0.73、0.81(P<0.05)。经直肠超声造影、miR-130b-3p、PGM5联合鉴别诊断早期前列腺癌的灵敏度、阴性预测值显著高于各自单独诊断,准确度高于血清miR-130b-3p、PGM5单独诊断(P<0.05)。结论经直肠超声造影联合血清miR-130b-3p、PGM5诊断早期前列腺癌的灵敏度、阴性预测值较高,且与病理结果的一致性最高。Objective To observe the changes in serum microRNA-130b-3p(miR-130b-3p),phosphoglucose mutase like protein 5(PGM5),and transrectal contrast-enhanced ultrasound parameters in patients with early prostate cancer,and to explore the combined value of the three in the differential diagnosis of early prostate cancer.Methods A total of 138 early stage prostate cancer patients in the People's Hospital of Tongren from May 2022 to July 2023 were selected as the prostate cancer group,and 145 patients with benign prostatic hyperplasia were selected as the benign prostatic hyperplasia group.Transrectal contrast-enhanced ultrasound was performed on the patients,and serum miR-130b-3p level was measured using qRT-PCR,and the PGM5 level was measured using enzyme-linked immunosorbent assay(ELISA).ROC curve was plotted to analyze the diagnostic value of various indicators for early prostate cancer,and the AUC was subjected to a Z-test;the consistency with the pathological results was tested using Kappa consistency test.Results The serum miR-130b-3p 1.32±0.35 level and the gradient(1.76±0.43)dB/s and peak intensity(15.27±0.64)dB of contrast-enhanced ultrasound parameters in the prostate cancer group were obviously higher than those in the benign hyperplasia group1.02±0.24,(1.35±0.34)dB/s,(14.35±0.27)dB,while serum PGM5(3.35±0.71)μg/L was obviously lower than that in the benign hyperplasia group(4.24±1.06)μg/L(P<0.05).The AUC for differential diagnosis of early prostate cancer using transrectal contrast-enhanced ultrasound,miR-130b-3p,and PGM5 alone and in combination was 0.86,0.80,0.81,and 0.93,respectively,the combined AUC was higher than the single AUC(P<0.05).The Kappa consistency coefficients between the results of transrectal contrast-enhanced ultrasound single and it combined serum indicators with pathological results were 0.73 and 0.81,respectively(P<0.05).The sensitivity and negative predictive value of combined transrectal contrast-enhanced ultrasound,miR-130b-3p,and PGM5 in the differential diagnosis of early pro

关 键 词：前列腺肿瘤 经直肠超声造影 微RNA-130b-3p 磷酸葡萄糖变位酶样蛋白5 诊断 

分 类 号：R737.25[医药卫生—肿瘤]